CCS Chemistry

IMMEDIATE ONLINE ACCEPTED (IOA) ARTICLE

IOA Posting Date: December 10 2024

TITLE: Discovery of a novel family of Gram-negative-active cationic cyclolipopeptides by motif search-guided chemical synthesis

AUTHORS: Fan Zhang, Fei Zhang, Xuchang Yu, Runze Sun, Yuzhu Wu, Yiwen Zhou and Lei Li

DOI: 10.31635/ccschem.024.202404925

CITE THIS: *CCS Chem.* **2024**, Just Accepted. DOI: 10.31635/ccschem.024.202404925

Discovery of a novel family of Gram-negative-active cationic cyclolipopeptides by motif search-guided chemical synthesis

Fan Zhang[1#], Fei Zhang[1#], Xuchang Yu[1,2#], Runze Sun[1], Yuzhu Wu[1], Yiwen Zhou[1] and Lei Li[1]*

[1] State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Rd., Shanghai, 200240

[2] State Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, 130 Meilong Rd., Shanghai 200237

*Corresponding Author: Lei Li: lei.li@sjtu.edu.cn

Abstract

Emerging antimicrobial resistance is a global public health crisis, which necessitates the development of antibiotics with novel structural scaffolds and modes-of-action (MOAs). Cationic cyclolipopeptides have been increasingly recognized as a kind of promising therapeutics against Gram-negative pathogens. By two-round motif searching of 8,982 sequenced genomes from 42 underexplored Gram-negative bacterial genera, here we identified a novel family of cationic cyclolipoeptide biosynthetic gene clusters (BGCs). Then, a synthetic-bioinformatic natural product (syn-BNP) approach that relies on structure prediction with high accuracy followed by chemical synthesis, was used to rapidly access their predicted products with six positively charged amino acids and nine D-amino acids out of 12 building blocks, thus generating chisopeptin and its five congeners. All of them showed good activities against a panel of Gram-negative pathogens with MIC of 2-8 μg/mL. Furthermore, chisopeptin was found to have a unique MOA to kill *Klebsiella pneumoniae* by possibly targeting the inner membrane protein YejM that regulates lipopolysaccharide biogenesis. The study of chisopeptin-type structures inspired by underexplored BGC families provides a productive approach to develop novel cyclolipopeptide-based therapeutics.

Keywords

Anti-microbial resistance, underexplored sources, natural products, cationic cyclolipopeptides, chemical synthesis, YejM

Introduction

The emergence of multidrug-resistant Gram-negative pathogens has become a major threat to global public health and necessitates the development of novel antibiotics with diverse modes of action (MOAs).[1-3] The chemical and mechanistic diversity of bacterial non-ribosomal peptides (NRPs) encoded by giant NRP synthetases (NRPSs) have been known as promising natural products for novel antibiotic discovery.[4-7] Multiple chemical modifications, such as cyclization, introduction of positively charged amino acids (PCAAs) or D-amino acids (D-AAs) and *N*-terminal fatty acid acylation, are usually used to optimize the physicochemical and proteolytic stability profiles of peptides, further improving their therapeutic potentials.[8] Particularly, cationic lipopeptides (CLPs) with at least two PCAAs, showed unique chemical properties for combating Gram-negative pathogens and have been developed for a series of clinically used antibiotics (i.e., colistin and polymyxin B).[9-11]

In the last ten years, underexplored Gram-negative bacteria have been increasingly recognized as rich sources of NRPs for the discovery of novel CLP-type antibiotics.[12-15] In our previous study, 8982 Gram-negative bacterial genomes from 42 underexplored genera were screened for novel CLP biosynthetic gene clusters (BGCs).[16] A linear CLP chospeptin was rapidly identified by structure prediction followed by solid-phase peptide synthesis, which showed good activities against different colistin-resistant Gram-negative pathogens by directly targeting lipopolysaccharide (LPS).[16] However, although the eight novel CLP BGCs were selected but we just synthesized their inspired linear products, possibly explaining why only chospeptin showed good antibacterial activity (Figure 1 and Table S1).[16] We proposed that the other seven CLP BGCs might encode cyclolipopeptides considering some hydrophilic AAs (i.e., Dap, Dab, Ser and Thr) as nucleophiles could realize peptide cyclization

through the C-terminal carboxyl. Actually, cyclization has emerged as the most widely used strategy to optimize the bioactivity of natural or synthetic peptides.[17] Considering more than 40 potential cyclolipopeptides inspired by the other seven CLP BGCs need to be synthesized, another AA modification (introduction of D-AAs) was used for the second-round motif search (Table S1). Natural peptides usually comprise L-amino acids (L-AAs), which are vulnerable to enzyme degradation. By contrast, introduction of D-AAs could often optimize the proteolytic stability of peptides, thus improving their bioactivity.[8,18,19] While multiple D-AAs in a single peptide was used for the second-round search, we found an interesting CLP2 BGC from *Chitinophaga solisilvae* CGMCC 1.12462, whose predicted p a).



Figure 1 | Two-round motif search for novel cationic lipopeptides (CLPs) with multiple D-amino acids from underexplored Gram-negative bacteria. One interesting CLP BGC whose encoded peptide contains nine D-amino acids was selected for structure prediction followed by solid-phase peptide synthesis as either linear or cyclic structures.

Experimental Methods

Chemical reagents, consumables and instruments

Standard *N*-Fmoc amino acids were purchased from GL Biochem (Shanghai, CN). Lipopolysaccharides (LPS) from *Escherichia coli* O55:B5 was purchased from Beijing InnoChem (Beijing, CN). GlcNAC, lipoteichoic acid,

muramyl dipeptide, MurNAC, pentapeptide and peptidoglycan were purchased from Bidepharm (Shanghai, CN). Reagents for solid-phase peptide synthesis (SPPS), including 2-chlorotrityl resin, dichloromethane (DCM), *N*,*N*-diisopropylethylamine (DIPEA), 4-dimethylaminopyridine (DMAP), *N*,*N*-dimethylformamide (DMF), O-(7-azabenzotriazol-1-yl)-*N*,*N*,*N*,*N*'-tetramethyluronium hexafluorophosphate (HATU), hexafluoroisopropanol (HFIP), (7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate (PyAOP) and trifluoroacetic acid (TFA), were purchased from GL Biochem (Shanghai, CN) or Shanghai Titan (Shanghai, CN).

An Agilent 1260 Series HPLC with UV detection and equipped with an XBridge Prep C18 130 Å column (10 x 150 mm, 5 μm) was used for peptide purification. For all liquid chromatography, solvent A = H_2O and solvent B = CH_3CN. An Agilent 1290 Series HPLC coupled to a 6546 Series QTOF mass spectrometer, equipped with a Phenomonex Kinetex PS C18 100 Å column (2.1 x 50 mm, 2.6 μm) and controlled by Masshunter software, was used to acquire the HPLC-HRMS data of synthetic peptides. A Bruker Avance DMX 700 MHz spectrometer equipped with cryogenic probes was used to acquire the ^{1}H, ^{13}C, DEPT135, COSY, HMBC and HSQC NMR spectra of synthetic peptides. All spectra were recorded at 25 °C in DMSO-d_6. Chemical shift values are reported in parts in million (ppm) and referenced to residual solvent signals: 2.50 ppm (^{1}H) and 39.52 ppm (^{13}C).

Solid Phase Peptide Synthesis (SPPS)

Standard Fmoc chemistry-based solid-phase peptide synthesis methods were used to synthesize peptides on 2-chlorotrityl chloride resin. Peptide synthesis started from the last AA of each peptide, which was loaded on 2-cholorotrityl resin (0.3 g, 0.552 mmol/g) and was swollen in DCM for 20 min, drained as well as washed with DMF (3 mL, 3x). By using Fmoc-protected amino acids (2 equiv., relative to resin loading) mixed with HATU (2 equiv.) and DIPEA (2 equiv.) in DMF (5 mL), individual amino acids were coupled step by step. Finally, coupling reactions were performed for 1 hr with occasional swirling and washed with DMF (3 mL, 3x).

For the synthesis of synCLP2-L, Fmoc-deprotection was done using 20% piperidine in DMF (3 mL) for 7 min and repeated twice. The resin was washed with DMF (3 mL, 5x) and then coupled with a subsequent *N*-Fmoc amino acid. Then, tetradecanoic acid was coupled into the end of linear peptide.

For the synthesis of synCLP2-C1, synCLP2-C7 (chisopeptin) and chisopeptin congeners, the alloc group of Dap was firstly removed by two rounds of palladium [$Pd(PPh_3)_4$]-catalyzed deprotection in DCM. In each round of deprotection, 0.25 equivalent plladium and 12 equivalent phenlsilane were added to resins suspended in DCM (3 mL) and reacted for 1 hr. Then, 2-chlorotrityl resin was removed by 20% HFIP in DCM for 2 hrs. Soluble peptides were further cyclized using PYAOP (8 equivalent) and DIPEA (30 equivalent) in DMF and extracted using DCM and H_2O with 1% formic acid. Air-dried cyclic peptides were dissolved in MeOH and completely dried under vacuum overnight.

For final cleavage, each Air-dried linear or cyclic peptides were dissolved in 3 mL of cleavage cocktail (95% v/v TFA, 2.5% v/v triisopropylsilane and 2.5% v/v H_2O) for 1.5 hrs. Then, to precipitate the peptide, a cold mixture of diethyl ether:hexane (1:1) was added and kept for 10 min at -20 °C. Peptide pellets were collected by centrifuging (2,500 g) for 5 min, redissolved in 5 mL of methanol and dried under vacuum overnight.

Peptide purification by HPLC

Crude synCLP2-L, synCLP2-C1, synCLP2-C7 (chisopeptin) and chisopeptin congeners were purified on a Xbridge Prep C18 HPLC column using a dual solvent system (A/B: H_2O/acetonitrile) (Figure S1). All synthetic peptides were eluted using a linear gradient from 20 to 45% gradient of B. The identity of each linear or cyclic peptide was confirmed by HRMS (Table S2 and Figure S2-4). Furthermore, ^{1}H, ^{13}C, DEPT135, COSY, HSQC and HMBC NMR spectra were recorded for chisopeptin and its five congeners (Figure S5-40). Structural assignments were performed with additional information from NMR experiments (Table S3-8).

Antimicrobial assays against Gram-positive bacteria, Gram-negative bacteria and fungi

All antimicrobial assays were performed in 96-well microtiter plates using a broth micro-dilution method. For fungi strains, overnight cultures were diluted 2,000-fold in YPD broth. Overnight cultures were diluted 1,000- and 10,000-fold in LB broth for *Enterococcus faecium* and *Staphylococcus aureus*, respectively. For other bacteria, overnight cultures were diluted 5,000-fold in LB broth. 100 μL of each diluted culture was mixed with 100 μL of LB broth containing a synthetic peptide at 2-fold serial dilutions across a 96-well microtiter plate row. The final concentration of each synthetic peptide ranged from 64 to 0.125 μg/mL. Plates were incubated at 37 °C (bacteria) or 30 °C (fungi) for 16 hrs. The lowest concentration that inhibited visible bacterial or fungal growth was recorded as the minimum inhibition concentration (MIC). All MIC assays were performed in duplicate (n = 2).

Antibiotic resistant mutant selection

A single *K. pneumoniae* ATCC 10031 colony was grown overnight at 37 °C in liquid LB medium. A portion of the overnight culture was diluted to ~10^8 cells per microliter, which were plated into solid LB with chisopeptin at 4x its MIC at 5 μL per well. The MICs of three individual appeared colonies were then determined using the broth micro-dilution method described above. Genome was extracted from cultures of colonies that showed an elevated MIC relative to the wild-type, and the resulting genome was sequenced by the MGI's DNBSEQ-T7 platform. Single-nucleotide polymorphisms (SNPs) for chisopeptin were identified using SNIPPY by mapping DNBSEQ-seq reads to the reference genome of *K. pneumoniae* ATCC 10031.

Cytotoxicity assessment

The human HeLa cell line was grown at 37 °C in a 5% CO_2 atmosphere in DMEM. To allow HeLa cells to adhere 96-well flat bottom microtiter plates, they were incubated in DMEM at 37 °C for 24 hrs. Then, the DMEM medium was replaced with 100 μL of fresh DMEM medium containing each synthetic peptide at 10 serially diluted concentrations ranging from 64 to 0.125 μg/mL. After 48 hrs at 37 °C, 10 μL of a CCK-8 solution was added into each well. After 2 hrs at 37 °C, the absorbance at 450 nm for each well was detected for measuring

the cytotoxicity of each synthetic peptide using a microplate reader. Taxol and DMSO were used as the positive and negative controls for the measurement of IC_{50} of each synthetic peptide against the human cell HeLa, respectively.

Results and Discussion

Prediction and synthesis of the CLP2 BGC products

More than 90% sequenced bacterial BGCs are not or lowly expressed under standard laboratory conditions, which could serve as rich sources for novel antibiotic discovery.[20-23] With the increasing accuracy of NP structure prediction algorithms and the advancement of modern synthetic organic chemistry, a bioactive compound could be rapidly generated by structure prediction followed by chemical synthesis.[24,25] The synthetic-bioinformatic natural product (syn-BNP) approach has been widely used for *de novo* and targeted discovery of diverse NRPs with novel structures or MOAs.[26-29] In this study, we used this syn-BNP approach to access linear or cyclic lipopeptide structures inspired by the CLP2 BGC for the test of antimicrobial activity. As shown in Figure 2a, all genes in the CLP2 BGC was predicted to form a single operon considering their expression were found to follow the same direction. The absence of any tailoring enzyme-encoding genes within 10 kb of the CLP2 NRPS genes suggested that the product of the CLP2 BGC could not be post-modified (Figure 2a and S39). Meanwhile, A-domain substrate specificity analysis allowed us to predict the building block incorporated by each A-domain found in the CLP2 BGC with high accuracy (Figure 2a and Table S9). Therefore, the linear peptide encoded by the CLP2 BGC was predicted to be the direct precursor to the final peptide. Meanwhile, considering that the two amino acids, $_D$-Dap-1 and $_D$-Dap-7, in predicted peptides, could serve as nucleophiles for cyclization of the predicted peptide through the C-terminal carboxyl, predicted CLP2 products could appear as either linear or cyclic structures. Meanwhile, the condensation starter (Cs) domain that usually couples a fatty acid onto the first amino acid of peptide were encoded by the CLP2 BGC (Figure S41). Among the known bacterial CLPs, tetradecanoic acid is one of the most common lipids, so all predicted CLP2 peptides

were *N*-terminal acylated with tetradecanoic acid.[30] Together, one linear predicted peptide (synCLP2-L) and two cyclic peptides (synCLP2-C1 and synCLP2-C7) that we predicted could arise from the CLP2 BGC, and were rapidly generated based on standard Fmoc chemistry-based solid-phase peptide synthesis (Figure 2b and S40).



Figure 2 | Discovery of chisopeptin. a, the CLP2 BGC contains two NRPS genes. The thioesterase (TE) domain releases the mature peptide from the final T domain as either a linear or cyclic mode. b, Diagrams of the three different peptide topologies that were made from the linear peptide predicted by the CLP2 BGC. c, MIC data against three Gram-negative or -positive bacteria for the three predicted synthetic peptides depicted in (b) (n=2). d, Structure of chisopeptin, which corresponds to C7 in (b).

Anti-microbial spectrum

All three synthetic structures were initially assayed for activity against three Gram-negative bacteria and three Gram-positive bacteria (Figure 2c). Although both synCLP2-C1 and synCLP2-C7 showed good activities against *Bacillus subtilis* ATCC 23857, only synCLP2-C7 that was cyclized through the hydroxyl of $_{D}$-Dap-7 showed good activity against two Gram-negative bacteria, including *Escherichia coli* DH5α and *Klebsiella pneumoniae* ATCC 10031, with minimum inhibitory concentration (MIC) from 4 to 8 μg/mL (Figure 2c). In broader bioactivity screening, synCLP2-C7 were also active against the two other Gram-negative pathogens, including *Erwinia amylovora* LXX and *Vibrio cholerae* ATCC 39315 (Table 1). Even at the highest concentration we tested (64 μg/mL), synCLP2-C7 did not show activity against two fungal strains or cytotoxicity to the human cell line HeLa

(Table 1). These results indicated that synCLP2-C7 we named chisopeptin had relatively narrow antimicrobial spectrum. Naturally occurring bacterial lipopeptides appear as either linear or cyclic structures.[6,7,31] It is very rare that one non-ribosomal lipopeptide BGC could encode both cyclic and linear peptides.[6,7,31,32] Considering

Table 1 | Activities of synCLP2-L, synCLP2-C1, chisopeptin and its eight congeners against microorganisms and human cell (MIC: μg/mL). Colistin and amphotericin B were used as the positive controls. ND: not detected.

Type	Pathogens	synCLP2-L	synCLP2-C1	Chisopeptin	Chisopeptin-NF	Chisopeptin-HA	Chisopeptin-DA	Chisopeptin-V11	Chisopeptin-V9	Chisopeptin-L6-V9	Chisopeptin-L6-F9	Chisopeptin-A4-L6-F9	Colistin	Amphotericin B
Gram-negative bacteria	*Escherichia coli* K12	>64	>64	4	>64	>64	4	4	8	4	2	4	2	ND
	Escherichia coli DH5α	>64	>64	8	>64	>64	8	4	8	8	4	8	<0.125	ND
	Escherichia coli ATCC 25922	>64	>64	4	>64	>64	8	8	8	4	2	8	0.5	ND
	Klebsiella pneumoniae ATCC 10031	>64	>64	4	>64	>64	4	4	8	8	2	4	0.5	ND
	Klebsiella pneumoniae RJA166	>64	>64	8	>64	>64	8	8	8	8	4	8	<0.125	ND
	Klebsiella pneumoniae RJF293	>64	>64	8	>64	>64	8	8	8	8	4	8	<0.125	ND
	Klebsiella pneumoniae RJF999	>64	>64	8	>64	>64	8	8	4	8	4	4	<0.125	ND
	Erwinia amylovora LXX	>64	>64	4	>64	64	4	4	4	4	2	2	0.25	ND
	Vibrio cholerae ATCC 39315	>64	32	4	>64	>64	8	8	4	8	2	4	>64	ND
	Acinetobacter baumannii ATCC 19606	>64	32	>64	>64	>64	64	>64	>64	>64	>64	32	1	ND
	Pseudomonas aeruginosa ATCC 15692	>64	>64	32	>64	>64	16	>64	>64	>64	32	>64	0.5	ND
Gram-positive bacteria	*Bacillus subtilis* ATCC 23857	32	4	4	>64	16	4	2	2	4	2	4	>64	ND
	Enterococcus faecalis ATCC 29212	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	ND
	Staphylococcus aureus USA300	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	ND
	Mycobacterium smegmatis mc2 155	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	ND
Fungi	*Candida albicans* ATCC 10231	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	0.5
	Saccharomyces cerevisiae BY4741	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	>64	0.25
Human cell line	HeLa	ND	ND	>64	ND	ND	ND	>64	>64	>64	>64	>64	>64	ND

only chisopeptin showed good anti-Gram-negative activity and either synCLP2-L or synCLP2-C1 was not active against tested pathogens, we speculate that chisopeptin is likely to be closest to natural product that the CLP2 BGC encodes (Figure 2d). The structure of chisopeptin was further confirmed using HRMS and 1D/2D NMR data (Table S2, Figure S1-2 and 5-10). Then, we synthesized three chisopeptin congeners by changing the length of fatty acid side chain, including chisopetin-NF without fatty acid side chain, chisopeptin-HA with the hexanoic acid as the fatty acid side chain and chisopeptin-DA with the decanic acid as the fatty acid side chain (Figure S1 and S3). As shown in Table 1, neither chisopeptin-NF nor chisopeptin-HA was active against tested Gram-negative bacteria and chisopeptin-DA showed compared anti-Gram-negative activity to chisopeptin

(tetradecanoic acid as the fatty acid side chain). The results indicate that a long fatty acid side chain is necessary to the activity of chisopeptin against Gram-negative bacteria.

Prediction and synthesis of the five chisopeptin congener BGC products



Figure 3 | Discovery of five chisopeptin congeners. a, The BGCs of CLP2 and five chisopeptin congeners. b, Linear peptide sequences of chisopeptin and its five congeners. c, MIC data against Gram-negative or Gram-positive pathogens for chisopeptin and its five congeners (n=2).

In our first-round search pipeline to discover novel CLP BGCs using at least two PCAAs in a peptide as the motif, only one representative CLP BGC among highly similar BGCs was chosen for next-step study. Therefore, we re-searched the predicted NRP database from 42 underexplored Gram-negative bacterial genera and found the five potential chisopeptin congener BGCs. Intriguingly, all the five BGCs are from the genus *Pedobacter*, which

has not traditionally been part of microbial NP discovery pipelines.[13] Similar to the CLP2 BGC, the expression of all genes in each BGC were also found to follow the same direction, which possibly form a single operon (Figure 3a and S42-46). Except for a MBL fold metallo-hydrolase encoded by the chisopeptin-L6-V9 BGC, there aren't any tailoring enzymes encoded by the five BGCs (Figure 3a and S41-45). Through A-domain substrate specificity analysis, we found that there were one to three different AAs in linear peptides predicted by the five BGCs from chisopeptin (Table S10-14, Figure 3b and S1). Then, all five chisopeptin congeners, including chisopeptin-V11, chisopeptin-V9, chisopeptin-L6-V9, chisopeptin-L6-F9 and chisopeptin-A4-L6-F9, were designed to be cyclized through the hydroxyl of $_D$-Dap-7 and rapidly generated by solid-phase peptide synthesis. Their structures were further confirmed using HRMS and 1D/2D NMR data (Table S2 and S4-8, Figure S4 and S11-40). Similar to chisopeptin, all five congeners showed similar antimicrobial spectra to chisopeptin and were active against four Gram-negative pathogens with MIC from 2 to 8 μg/mL. In a subset of these congeners, antibacterial activities of chisopeptin-L6-F9 in particular, were two-fold higher than those of chisopeptin (Figure 3c and Table 1). Collectively, a novel family of cationic cyclolipopeptides, including chisopeptin and its five congeners, were identified with good activities against a panel of Gram-negative pathogens.

Mode of action studies

Then, we tested whether *K. pneumoniae* ATCC 10031 would be lysed using 4× the MIC of chisopeptin, and found that chisopeptin could not result in rapid bacteriolysis (Figure 4a). Considering that chisopeptin as a cationic cyclolipopeptide might target LPS in the outer membrane of Gram-negative pathogens, we assayed for the ability of LPS to suppress chisopeptin to explore MOA of chisopeptin. However, when LPS was added to the LB medium, the MIC of chisopeptin did not increase in a dose-dependent manner for *K. pneumoniae*, which indicated that chisopetin could not target LPS and its anti-Gram-negative activity was not dependent on LPS (Figure 4b). Then, we tried to raise mutants to chisopeptin and selected *K. pneumoniae* mutants that could grow on 4× MIC of chisopeptin. At 4× chisopeptin's MIC resistant mutants appeared at a frequency of 1×10^{-6}. We sequenced the genomes of three representative resistant strains (Figure 4c). In all cases, the resistant

strains contained a mutation (in-frame or frame-shift deletion) in the gene *yejM* and no other mutations were detected in the genome (Figure 4d). When the gene *yejM* under the expression of the constitutive promoter *rpsLp* was complemented to the three *K. pneumoniae* mutants, all of them became sensitive to chisopeptin again（Figure



Figure 4 | Mode-of-action of chisopeptin against the strain *K. pneumoniae* ATCC 10031. a, Bactericidal activity of chisopeptin against *K. pneumoniae*. Cultures were incubated with each antibiotic at 4×its MIC. b, The *K. pneumoniae* antibacterial activity of chisopeptin was determined in the presence of different concentrations of LPS (n = 2). c, The MICs (μg/mL) of chisopeptin against *K. pneumoniae* mutants (n = 2). Colistin was used as the positive control. d, The mutated results of the gene *yejM* in the three chisopeptin resistant *K. pneumoniae* strains. e, The MICs (μg/mL) of chisopeptin against *K. pneumoniae* mutants with pET28a or pET-*yejM* (n = 2). Colistin was used as the positive control. f, A proposed model-of-action of chisopeptin against Gram-negative pathogens (i.e., *K. pneumoniae*).

4e). YejM, as an inner membrane protein, is a key regulator of outer membrane integrity and LPS biogenesis by directly detecting LPS on the periplasmic leaflet of the inner membrane in Gram-negative bacteria.[33,34] In

detail, YejM as an anti-adaptor protein can compete with FtsH for LapB to inhibit LpxC degradation (Figure 4f).[35] Deletion of the gene *yejM* could promote LpxC degradation, thus resulting in reduced LPS levels.[34,36] Previous studies indicated that the mutation of *yejM* also led to higher resistance to chloramphenicol in *E. coli*.[37] Considering that chisopeptin did not directly target LPS, we proposed that chisopeptin might target the inner membrane protein YejM, thus interrupting normal LPS biogenesis and exhibiting anti-Gram-negative activity (Figure 4f). To explore whether chisopeptin could directly bind to YejM *in vitro*, we tried to express and purify YejM but failed, which might be because YejM is a membrane protein (data not shown). The more detailed MOA for chisopeptin could be further explored in the future.

Conclusion

Infections caused by multidrug-resistant Gram-negative pathogens are threatening to overwhelm healthcare systems worldwide.[2,3] In recent years, underexplored Gram-negative bacteria exhibit large biosynthetic potential for the discovery of novel antimicrobial peptides.[12-15] In this study, we used the two-round motif search pipelines, including at least two PCAAs and multiple D-AAs, to screen >8900 underexplored Gram-negative bacterial genomes and identified a novel family of cationic cyclolipopeptides (chisopeptin and its five congeners) with good activities against a panel of Gram-negative pathogens. All six synBNPs have very unique structural scaffolds, which contain six PCAAs and nine D-AAs out of 12 building blocks. Noteworthy, the kind of cationic cyclolipopeptides was identified to have a potential MOA to kill *K. pneumoniae* by possibly targeting the inner membrane protein YejM that regulates LPS biogenesis. Considering that *K. pneumoniae* has relatively high frequency to generate resistant mutants to chisopeptin, combinations of chiospeptin-type antibiotics and of known Gram-negative-active drugs with different MOAs (i.e., penicillin-binding protein-targeting meropenem, ribosome-targeting amikacin and DNA-targeting moxifloxacin), provide an alternative strategy for further pre-clinical development of this novel family of cationic cyclolipopeptides.[38] As seen with the characterization of bacterial CLPs, the study of chisopeptin-type structures inspired by underexplored BGC families provides an alternative approach to develop novel CLP-based therapeutics with diverse MOAs.[39,40]

Supporting Information

Supporting Information is available and includes chisopeptin and its congeners domain prediction tables, chisopeptin and its congeners BGC analysis, chisopeptin and its congeners HRMS and NMR spectra.

Conflict of Interest

There is no conflict of interest to report.

Funding Information

This work was supported by the National Key Research and Development Program of China (2023YFA0916200 and 2023YFA0914200), the National Natural Science Foundation of China (32370070) and Shanghai Municipal Science and Technology Major Project.

Acknowledgments

We thank Prof. Jianming Zhang and Xiaowen Wang at Shanghai Jiao Tong University for cytotoxicity assessment.

References

1. Abbas, A.; Barkhouse, A.; Hackenberger, D.; Wright, G. D. Antibiotic resistance: A key microbial survival mechanism that threatens public health. *Cell Host Microbe* **2024**, *32*, 837-851.

2. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **2022**, *400*, 2221-2248.

3. Zowawi, H. M.; Harris, P. N.; Roberts, M. J.; Tambyah, P. A.; Schembri, M. A.; Pezzani, M. D.; Williamson, D. A.; Paterson, D. L. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. *Nat. Rev. Urol.* **2015**, *12*, 570-584.

4. Lewis, K.; Lee, R. E.; Brötz-Oesterhelt, H.; Hiller, S.; Rodnina, M. V.; Schneider, T.; Weingarth, M.; Wohlgemuth, I. Sophisticated natural products as antibiotics. *Nature* **2024**, *632*, 39-49.

5. Atanasov, A. G.; Zotchev, S. B.; Dirsch, V. M.; International Natural Product Sciences Taskforce; Supuran, C. T. Natural products in drug discovery: advances and opportunities. *Nat. Rev. Drug Discov.* **2021**, *20*, 200-216.

6. Liu, Y.; Ding, S.; Shen, J.; Zhu, K. Nonribosomal antibacterial peptides that target multidrug-resistant bacteria. *Nat. Prod. Rep.* **2019**, *36*, 573-592.

7. Chen, J.; Wang, W.; Hu, X.; Yue, Y.; Lu, X.; Wang, C.; Wei, B.; Zhang, H.; Wang, H. Medium-sized peptides from microbial sources with potential for antibacterial drug development. *Nat. Prod. Rep*. **2024**, *41*, 1235-1263.

8. Fetse, J.; Kandel, S.; Mamani, U. F.; Cheng, K. Recent advances in the development of therapeutic peptides. *Trends Pharmacol. Sci.* **2023**, *44*, 425-441.

9. Biswas, S.; Brunel, J. M.; Dubus, J. C.; Reynaud-Gaubert, M.; Rolain, J. M. Colistin: an update on the antibiotic of the 21st century. *Expert Rev. Anti-Infect.* **2012**, *10*, 917-934.

10. Li, Y. X.; Zhong, Z.; Zhang, W. P.; Qian, P. Y. Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining. *Nat. Commun.* **2018**, *9*, 3273.

11. Wang, Z.; Koirala, B.; Hernandez, Y.; Zimmerman, M.; Park, S.; Perlin, D. S.; Brady, S. F. A naturally inspired antibiotic to target multidrug-resistant pathogens. *Nature* **2022**, *601*, 606-611.

12. Li, L. Accessing hidden microbial biosynthetic potential from underexplored sources for novel drug discovery. *Biotechnol. Adv.* **2023**, *66*, 108176.

13. Masschelein, J.; Jenner, M.; Challis, G. L. Antibiotics from Gram-negative bacteria: a comprehensive overview and selected biosynthetic highlights. *Nat. Prod. Rep.* **2017**, *34*, 712-783.

14. Brinkmann, S.; Spohn, M. S.; Schäberle, T. F. Bioactive natural products from Bacteroidetes. *Nat. Prod. Rep.* **2022**, *39*, 1045-1065.

15. Brinkmann, S.; Kurz, M.; Patras, M. A.; Hartwig, C.; Marner, M.; Leis, B.; Billion, A.; Kleiner, Y.; Bauer, A.; Toti, L.; Pöverlein, C.; Hammann, P. E.; Vilcinskas, A.; Glaeser, J.; Spohn, M.; Schäberle, T. F. Genomic and chemical decryption of the bacteroidetes phylum for its potential to biosynthesize natural products. *Microbiol. Spectr.* **2022**, *10*, e0247921.

16. Sun, R.; You, R.; Yu, X.; Zhao, D.; Li, L. Discovery and synthesis of a Gram-negative-active cationic lipopeptide antibiotic inspired by primary sequences from underexplored Gram-negative bacteria. *Org. Lett.* **2024**, *26*, 1348-1352.

17. Zhang, H.; Chen, S. Cyclic peptide drugs approved in the last two decades (2001-2021). *RSC Chem. Biol.* **2021**, *3*, 18-31.

18. Armstrong, D. W.; Berthod, A. Occurrence of D-amino acids in natural products. *Nat. Prod. Bioprospect.* **2023**, *13*, 47.

19. Abdulbagi, M.; Wang, L.; Siddig, O.; Di, B.; Li, B. D-amino acids and D-amino acid-containing peptides: potential disease biomarkers and therapeutic targets? *Biomolecules* **2021**, *11*, 1716.

20. Rutledge, P. J.; Challis, G. L. Discovery of microbial natural products by activation of silent biosynthetic gene clusters. *Nat. Rev. Microbiol.* **2015**, *13*, 509-523.

21. Gavriilidou, A.; Kautsar, S. A.; Zaburannyi, N.; Krug, D.; Müller, R.; Medema, M. H.; Ziemert, N. Compendium of specialized metabolite biosynthetic diversity encoded in bacterial genomes. *Nat. Microbiol.* **2022**, *7*, 726-735.

22. Medema, M. H.; de Rond, T.; Moore, B. S. Mining genomes to illuminate the specialized chemistry of life. *Nat. Rev. Genet.* **2021**, *22*, 553-571.

23. Hemmerling, F.; Piel, J. Strategies to access biosynthetic novelty in bacterial genomes for drug discovery. *Nat. Rev. Drug Discov.* **2022**, *21*, 359-378.

24. Blin, K.; Shaw, S.; Augustijn, H. E.; Reitz, Z. L.; Biermann, F.; Alanjary, M.; Fetter, A.; Terlouw, B. R.; Metcalf, W. W.; Helfrich, E. J. N.; van Wezel, G. P.; Medema, M. H.; Weber, T. antiSMASH 7.0: new and improved predictions for detection, regulation, chemical structures and visualisation. *Nucleic Acids Res.* **2023**, *51*, W46-W50.

25. Stachelhaus, T.; Mootz, H. D.; Marahiel, M. A. The specificity-conferring code of adenylation domains in nonribosomal peptide synthetases. *Chem. Biol.* **1999**, *6*, 493-505.

26. Chu, J.; Vila-Farres, X.; Inoyama, D.; Ternei, M.; Cohen, L. J.; Gordon, E. A.; Reddy, B. V.; Charlop-Powers, Z.; Zebroski, H. A.; Gallardo-Macias, R.; Jaskowski, M.; Satish, S.; Park, S.; Perlin, D. S.; Freundlich, J. S.; Brady, S. F. Discovery of MRSA active antibiotics using primary sequence from the human microbiome. *Nat. Chem. Biol.* **2016**, *12*, 1004-1006.

27. Chu, J.; Vila-Farres, X.; Brady, S. F. Bioactive synthetic-bioinformatic natural product cyclic peptides inspired by nonribosomal peptide synthetase gene clusters from the human microbiome. *J. Am. Chem. Soc.* **2019**, *141*, 15737-15741.

28. Wang, Z.; Koirala, B.; Hernandez, Y.; Zimmerman, M.; Brady, S. F. Bioinformatic prospecting and synthesis of a bifunctional lipopeptide antibiotic that evades resistance. *Science* **2022**, *376*, 991-996.

29. Li, L.; Koirala, B.; Hernandez, Y.; MacIntyre, L. W.; Ternei, M. A.; Russo, R.; Brady, S. F. Identification of structurally diverse menaquinone-binding antibiotics with *in vivo* activity against multidrug-resistant pathogens. *Nat. Microbiol.* **2022**, *7*, 120-131.

30. Rausch, C.; Hoof, I.; Weber, T.; Wohlleben, W.; Huson, D. H. Phylogenetic analysis of condensation domains in NRPS sheds light on their functional evolution. *BMC Evol. Biol.* **2007**, *7*, 78.

31. Zhang, S.; Chen, Y.; Zhu, J.; Lu, Q.; Cryle, M. J.; Zhang, Y.; Yan, F. Structural diversity, biosynthesis, and biological functions of lipopeptides from *Streptomyces*. *Nat. Prod. Rep*. **2023**, *40*, 557-594.

32. Götze, S.; Vij, R.; Burow, K.; Thome, N.; Urbat, L.; Schlosser, N.; Pflanze, S.; Müller, R.; Hänsch, V. G.; Schlabach, K.; Fazlikhani, L.; Walther, G.; Dahse, H. M.; Regestein, L.; Brunke, S.; Hube, B.; Hertweck, C.; Franken, P.; Stallforth, P. Ecological niche-inspired genome mining leads to the discovery of crop-protecting nonribosomal lipopeptides featuring a transient amino acid building block. *J. Am. Chem. Soc.* 2**023**, *145*, 2342-2353.

33. Guest, R. L.; Rutherford, S. T.; Silhavy, T. J. Border control: regulating LPS biogenesis. *Trends Microbiol*. **2021**, *29*, 334-345.

34. Clairfeuille, T.; Buchholz, K. R.; Li, Q.; Verschueren, E.; Liu, P.; Sangaraju, D.; Park, S.; Noland, C. L.; Storek, K. M.; Nickerson, N. N.; Martin, L.; Dela Vega, T.; Miu, A.; Reeder, J.; Ruiz-Gonzalez, M.; Swem, D.; Han, G.; DePonte, D. P.; Hunter, M. S.; Gati, C.; Shahidi-Latham, S.; Xu, M.; Skelton, N.; Sellers, B. D.; Skippington, E.; Sandoval, W.; Hanan, E. J.; Payandeh, J.; Rutherford, S. T. Structure of the essential inner membrane lipopolysaccharide-PbgA complex. *Nature* **2020**, *584*, 479-483.

35. Shu, S.; Mi, W. Regulatory mechanisms of lipopolysaccharide synthesis in *Escherichia coli*. *Nat. Commun.* **2022**, *13*, 4576.

36. Fivenson, E. M.; Bernhardt, T. G. An essential membrane protein modulates the proteolysis of LpxC to control lipopolysaccharide synthesis in *Escherichia coli*. *mBio* **2020**, *11*, e00939-20.

37. Duo M, Hou S, Ren D. Identifying *Escherichia coli* genes involved in intrinsic multidrug resistance. *Appl. Microbiol. Biotechnol.* **2008**, *81*, 731-41.

38. Tyers, M., Wright, G. S. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. *Nat. Rev. Microbiol.* **2019**, *17*, 141-155.

39. Zhao, S.; Adamiak, J. W.; Bonifay, V.; Mehla, J.; Zgurskaya, H. I.; Tan, D. S. Defining new chemical space for drug penetration into Gram-negative bacteria. *Nat. Chem. Biol.* **2020**, *16*, 1293-1302.

40. Miethke, M.; Pieroni, M.; Weber, T.; Brönstrup, M.; Hammann, P.; Halby, L.; Arimondo, P. B.; Glaser, P.; Aigle, B.; Bode, H. B.; Moreira, R.; Li, Y.; Luzhetskyy, A.; Medema, M. H.; Pernodet, J. L.; Stadler, M.; Tormo, J. R.; Genilloud, O.; Truman, A. W.; Weissman, K. J.; Takano, E.; Sabatini, S.; Stegmann, E.; Brötz-Oesterhelt, H.; Wohlleben, W.; Seemann, M.; Empting, M.; Hirsch, A. K. H.; Loretz, B.; Lehr, C. M.; Titz, A.; Herrmann, J.; Jaeger, T.; Alt, S.; Hesterkamp, T.; Winterhalter, M.; Schiefer, A.; Pfarr, K.; Hoerauf, A.; Graz, H.; Graz, M.; Lindvall, M.; Ramurthy, S.; Karlén, A.; van Dongen, M.; Petkovic, H.; Keller, A.; Peyrane, F.; Donadio, S.; Fraisse, L.; Piddock, L. J. V.; Gilbert, I. H.; Moser, H. E.; Müller, R. Towards the sustainable discovery and development of new antibiotics. *Nat. Rev. Chem.* **2021**, *5*, 726-749

Table of Contents Graphic